Merck & Co. Joins Competitive BTK Research Space With $2.7bn ArQule Buy

 
• By Jessica Merrill

ArQule's lead candidate, ARQ 531, is a novel BTK inhibitor in Phase II development that could work in patients with B-cell malignancies resistant to existing BTK inhibitors like Imbruvica.

SOLD red stamp. Flat vector icon - Vector
Merck is buying ArQule for $2.7bn in cash

More from Deals

More from Business